annb0t
Top 20
Pacira Biosciences PCRX announced that the FDA has accepted for review its supplemental new drug application (sNDA) for Exparel. The sNDA seeks to expand Exparelâs label to include a single-dose sciatic nerve block in the popliteal fossa and a femoral nerve block in the adductor canal.
A decision from the FDA is expected on Nov 13, 2023.
The sNDA filing was based on results from two successful phase III studies of Exparel. The drug achieved statistically significant and clinically mean...
>>> Read more: Pacira's (PCRX) sNDA for Exparel Accepted for FDA Review
A decision from the FDA is expected on Nov 13, 2023.
The sNDA filing was based on results from two successful phase III studies of Exparel. The drug achieved statistically significant and clinically mean...
>>> Read more: Pacira's (PCRX) sNDA for Exparel Accepted for FDA Review
